FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All Resources2023 US Conference - Sponsorship and Exhibitor Overview
Topic: Conference
Video
Free
Countdown to Brexit: Can your clinical supply chain pass the Brexit pressure test
Topics: Pharma Industry, Politics
White Paper
Members
Challenges of the Cell, Gene, CAR-T and Personalized Medicine Supply Chains
Topics: Cold Chain, Conference, Supply Chain
Video
Members
